Pomalyst 2 MG, 4 MG
Ended Awarded Last action
- Contract number
- 36C24526N0474
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $138,603
Award facts
- Contract value 100% obligated
- $138,603.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$91 | |
| Original award | $138,694 |
About this award
Bristol-Myers Squibb Company received a delivery order valued at $138,603.09 under its Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs to supply POMALYST 2 mg and 4 mg tablets to Veterans Integrated Service Network 5, with an ultimate completion date of April 30, 2026. This contract is issued as a firm fixed-price Blanket Purchase Agreement (BPA) call with no set-aside designations and represents a child award under the broader Pharmaceuticals and Drugs (FSS-61-IB) master schedule. The parent FSS contract, valued at $12.3 billion and extending through April 2029, was awarded to Bristol-Myers Squibb on May 1, 2024, establishing the pricing framework and terms under which this and numerous other delivery orders have been issued across multiple Veterans Integrated Service Networks since 2022.
POMALYST (pomalidomide) is a specialized oncology pharmaceutical indicated for treatment of hematologic malignancies, reflecting the Department of Veterans Affairs' commitment to providing advanced cancer treatments and standard-of-care therapies to eligible veterans. Bristol-Myers Squibb, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, has demonstrated sustained performance as a critical federal supplier through its GSA Schedule contract, having fulfilled over fifty documented delivery orders for oncology and cell therapy products across the VA healthcare system. The performance location for this delivery order is established at Memphis, Tennessee, supporting the VA's oncology and specialized medicine mission within the regional VISN 5 network.
Quick answers
Who was awarded contract 36C24526N0474?
36C24526N0474 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on April 7, 2026.
How much is contract 36C24526N0474 worth?
The government has obligated $138,603 on 36C24526N0474.
Is contract 36C24526N0474 an order under another contract?
Yes. 36C24526N0474 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0474 competed?
The extent of competition for 36C24526N0474 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award